Zimbabwe has rejected a significant American healthcare agreement valued at $367m (272 million pounds) spanning five years over Washington's demand for confidential biological samples.
This rejection came to light following a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesperson has since clarified that the US was demanding access to biological samples for scientific study and commercial purposes while was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued negotiations to secure a deal agreeable to both sides so the nation's vital HIV programme can continue.
Broader Background
This development comes after a similar case in neighbouring Kenya, where a court blocked a similar deal with the US after legal challenges were raised about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
According to reports, 16 nations in Africa have so far agreed to these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Put simply, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our population should a future disease outbreak arise."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining frameworks previously set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to deal with future global health emergencies.
"This framework is designed to ensure that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to continued discussions with our American counterparts on how subsequent collaboration could be designed in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but recommended that negotiations must proceed given that a large portion of the country's HIV programmes were funded by external financing.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group commented.
The situation highlights the complex tensions between receiving vital foreign assistance and protecting a country's data in an increasingly data-driven world.